Trial Outcomes & Findings for Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy (NCT NCT05034289)
NCT ID: NCT05034289
Last Updated: 2026-05-18
Results Overview
Measured using the 4-item Acceptability of Intervention Measure (AIM). Scores range from 1 to 5, with higher scores indicating greater acceptability. Cronbach's α = .85.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
81 participants
Primary outcome timeframe
Immediately following completion of the PINPOINT intervention during the pilot testing session (same day; intervention and exit survey completed within approximately 30-40 minutes total).
Results posted on
2026-05-18
Participant Flow
Participants were recruited between June 2021 and April 2022 through electronic medical record screening at the Rutgers Cancer Institute, University Hospital-Newark, and affiliated RWJBarnabas Health oncology sites. Additional recruitment occurred through Community Advisory Board (CAB) networks and community-based outreach.
A total of 81 participants were enrolled across two phases of the study. In the Key Informant Interview Phase, 48 participants enrolled and completed their interviews. In the Pilot Intervention Phase, 33 participants enrolled. Of these, 30 were analyzed.
Participant milestones
| Measure |
Key Informant Patients
Black or African American adults with solid tumor cancers who completed a survey and an in-depth interview about experiences, knowledge, and attitudes related to precision oncology, immunotherapy, and clinical trials.
|
Key Informant Relatives
Adult relatives, spouses, or caregivers of Black or African American cancer patients who completed a survey and an in-depth interview to share perspectives on cancer care, decision-making, and informational needs related to precision oncology and clinical trials.
|
Key Informant Providers
Oncology health care professionals (including physicians, nurses, social workers, and patient navigators) who participated in an in-depth interview about barriers, facilitators, and cultural considerations impacting precision oncology and clinical trial participation among Black patients.
|
PINPOINT Digital Education Tool (Pilot Test)
Newly diagnosed Black or African American adults with solid tumor cancers who used the PINPOINT digital education tool, a culturally tailored website providing information on precision oncology, clinical trials, and immunotherapy. The tool included interactive features such as videos, a chatbot, and downloadable communication aids. Participants completed pre- and post-intervention surveys
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
20
|
15
|
13
|
33
|
|
Overall Study
Completed Interview/ Intervention (net)
|
20
|
15
|
13
|
30
|
|
Overall Study
COMPLETED
|
20
|
15
|
13
|
30
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
3
|
Reasons for withdrawal
| Measure |
Key Informant Patients
Black or African American adults with solid tumor cancers who completed a survey and an in-depth interview about experiences, knowledge, and attitudes related to precision oncology, immunotherapy, and clinical trials.
|
Key Informant Relatives
Adult relatives, spouses, or caregivers of Black or African American cancer patients who completed a survey and an in-depth interview to share perspectives on cancer care, decision-making, and informational needs related to precision oncology and clinical trials.
|
Key Informant Providers
Oncology health care professionals (including physicians, nurses, social workers, and patient navigators) who participated in an in-depth interview about barriers, facilitators, and cultural considerations impacting precision oncology and clinical trial participation among Black patients.
|
PINPOINT Digital Education Tool (Pilot Test)
Newly diagnosed Black or African American adults with solid tumor cancers who used the PINPOINT digital education tool, a culturally tailored website providing information on precision oncology, clinical trials, and immunotherapy. The tool included interactive features such as videos, a chatbot, and downloadable communication aids. Participants completed pre- and post-intervention surveys
|
|---|---|---|---|---|
|
Overall Study
Found Ineligible
|
0
|
0
|
0
|
3
|
Baseline Characteristics
Household Income data were not collected from Key Informant Providers.
Baseline characteristics by cohort
| Measure |
Key Informant Patients
n=20 Participants
Black or African American adults with solid tumor cancers who completed a survey and an in-depth interview about experiences, knowledge, and attitudes related to precision oncology, immunotherapy, and clinical trials.
|
Key Informant Relatives
n=15 Participants
Adult relatives, spouses, or caregivers of Black or African American cancer patients who completed a survey and an in-depth interview to share perspectives on cancer care, decision-making, and informational needs related to precision oncology and clinical trials.
|
Key Informant Providers
n=13 Participants
Oncology health care professionals (including physicians, nurses, social workers, and patient navigators) who participated in an in-depth interview about barriers, facilitators, and cultural considerations impacting precision oncology and clinical trial participation among Black patients.
|
PINPOINT Digital Education Tool (Pilot Test)
n=33 Participants
Newly diagnosed Black or African American adults with solid tumor cancers who used the PINPOINT digital education tool, a culturally tailored website providing information on precision oncology, clinical trials, and immunotherapy. The tool included interactive features such as videos, a chatbot, and downloadable communication aids. Participants completed pre- and post-intervention surveys
|
Total
n=81 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Continuous
|
57.45 years
STANDARD_DEVIATION 10.3 • n=20 Participants
|
48.53 years
STANDARD_DEVIATION 7.3 • n=15 Participants
|
41.38 years
STANDARD_DEVIATION 7.3 • n=13 Participants
|
57.6 years
STANDARD_DEVIATION 12 • n=33 Participants
|
53.3 years
STANDARD_DEVIATION 13.4 • n=81 Participants
|
|
Sex/Gender, Customized
Female
|
18 Participants
n=20 Participants
|
4 Participants
n=15 Participants
|
9 Participants
n=13 Participants
|
24 Participants
n=33 Participants
|
55 Participants
n=81 Participants
|
|
Sex/Gender, Customized
Male
|
2 Participants
n=20 Participants
|
9 Participants
n=15 Participants
|
4 Participants
n=13 Participants
|
9 Participants
n=33 Participants
|
24 Participants
n=81 Participants
|
|
Sex/Gender, Customized
Transgender
|
0 Participants
n=20 Participants
|
2 Participants
n=15 Participants
|
0 Participants
n=13 Participants
|
0 Participants
n=33 Participants
|
2 Participants
n=81 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=20 Participants
|
7 Participants
n=15 Participants
|
1 Participants
n=13 Participants
|
1 Participants
n=33 Participants
|
10 Participants
n=81 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
19 Participants
n=20 Participants
|
8 Participants
n=15 Participants
|
12 Participants
n=13 Participants
|
32 Participants
n=33 Participants
|
71 Participants
n=81 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=20 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=13 Participants
|
0 Participants
n=33 Participants
|
0 Participants
n=81 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=20 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=13 Participants
|
0 Participants
n=33 Participants
|
0 Participants
n=81 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=20 Participants
|
0 Participants
n=15 Participants
|
2 Participants
n=13 Participants
|
0 Participants
n=33 Participants
|
2 Participants
n=81 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=20 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=13 Participants
|
0 Participants
n=33 Participants
|
0 Participants
n=81 Participants
|
|
Race (NIH/OMB)
Black or African American
|
20 Participants
n=20 Participants
|
15 Participants
n=15 Participants
|
1 Participants
n=13 Participants
|
33 Participants
n=33 Participants
|
69 Participants
n=81 Participants
|
|
Race (NIH/OMB)
White
|
0 Participants
n=20 Participants
|
0 Participants
n=15 Participants
|
7 Participants
n=13 Participants
|
0 Participants
n=33 Participants
|
7 Participants
n=81 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=20 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=13 Participants
|
0 Participants
n=33 Participants
|
0 Participants
n=81 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=20 Participants
|
0 Participants
n=15 Participants
|
3 Participants
n=13 Participants
|
0 Participants
n=33 Participants
|
3 Participants
n=81 Participants
|
|
Household Income
<20,000
|
5 Participants
n=20 Participants • Household Income data were not collected from Key Informant Providers.
|
1 Participants
n=15 Participants • Household Income data were not collected from Key Informant Providers.
|
—
|
11 Participants
n=33 Participants • Household Income data were not collected from Key Informant Providers.
|
17 Participants
n=68 Participants • Household Income data were not collected from Key Informant Providers.
|
|
Household Income
20,001-50,000
|
1 Participants
n=20 Participants • Household Income data were not collected from Key Informant Providers.
|
3 Participants
n=15 Participants • Household Income data were not collected from Key Informant Providers.
|
—
|
11 Participants
n=33 Participants • Household Income data were not collected from Key Informant Providers.
|
15 Participants
n=68 Participants • Household Income data were not collected from Key Informant Providers.
|
|
Household Income
>50,001
|
14 Participants
n=20 Participants • Household Income data were not collected from Key Informant Providers.
|
11 Participants
n=15 Participants • Household Income data were not collected from Key Informant Providers.
|
—
|
10 Participants
n=33 Participants • Household Income data were not collected from Key Informant Providers.
|
35 Participants
n=68 Participants • Household Income data were not collected from Key Informant Providers.
|
|
Household Income
Missing
|
0 Participants
n=20 Participants • Household Income data were not collected from Key Informant Providers.
|
0 Participants
n=15 Participants • Household Income data were not collected from Key Informant Providers.
|
—
|
1 Participants
n=33 Participants • Household Income data were not collected from Key Informant Providers.
|
1 Participants
n=68 Participants • Household Income data were not collected from Key Informant Providers.
|
|
Highest Education
Less than high school
|
1 Participants
n=20 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=13 Participants
|
6 Participants
n=33 Participants
|
7 Participants
n=81 Participants
|
|
Highest Education
High school grad/GED
|
1 Participants
n=20 Participants
|
6 Participants
n=15 Participants
|
0 Participants
n=13 Participants
|
15 Participants
n=33 Participants
|
22 Participants
n=81 Participants
|
|
Highest Education
College graduate or higher
|
18 Participants
n=20 Participants
|
9 Participants
n=15 Participants
|
13 Participants
n=13 Participants
|
12 Participants
n=33 Participants
|
52 Participants
n=81 Participants
|
|
Cancer Diagnosis
Breast
|
12 Participants
n=20 Participants • Cancer Diagnosis data were not collected from Key Informant Relatives or Key Informant Providers.
|
—
|
—
|
15 Participants
n=33 Participants • Cancer Diagnosis data were not collected from Key Informant Relatives or Key Informant Providers.
|
27 Participants
n=53 Participants • Cancer Diagnosis data were not collected from Key Informant Relatives or Key Informant Providers.
|
|
Cancer Diagnosis
Prostate
|
1 Participants
n=20 Participants • Cancer Diagnosis data were not collected from Key Informant Relatives or Key Informant Providers.
|
—
|
—
|
7 Participants
n=33 Participants • Cancer Diagnosis data were not collected from Key Informant Relatives or Key Informant Providers.
|
8 Participants
n=53 Participants • Cancer Diagnosis data were not collected from Key Informant Relatives or Key Informant Providers.
|
|
Cancer Diagnosis
Ovarian
|
1 Participants
n=20 Participants • Cancer Diagnosis data were not collected from Key Informant Relatives or Key Informant Providers.
|
—
|
—
|
1 Participants
n=33 Participants • Cancer Diagnosis data were not collected from Key Informant Relatives or Key Informant Providers.
|
2 Participants
n=53 Participants • Cancer Diagnosis data were not collected from Key Informant Relatives or Key Informant Providers.
|
|
Cancer Diagnosis
Other/multiple cancers
|
6 Participants
n=20 Participants • Cancer Diagnosis data were not collected from Key Informant Relatives or Key Informant Providers.
|
—
|
—
|
10 Participants
n=33 Participants • Cancer Diagnosis data were not collected from Key Informant Relatives or Key Informant Providers.
|
16 Participants
n=53 Participants • Cancer Diagnosis data were not collected from Key Informant Relatives or Key Informant Providers.
|
|
Cancer Stage
Stage I
|
11 Participants
n=20 Participants • Cancer Stage data were not collected from Key Informant Relatives or Key Informant Providers.
|
—
|
—
|
13 Participants
n=33 Participants • Cancer Stage data were not collected from Key Informant Relatives or Key Informant Providers.
|
24 Participants
n=53 Participants • Cancer Stage data were not collected from Key Informant Relatives or Key Informant Providers.
|
|
Cancer Stage
Stage II
|
5 Participants
n=20 Participants • Cancer Stage data were not collected from Key Informant Relatives or Key Informant Providers.
|
—
|
—
|
11 Participants
n=33 Participants • Cancer Stage data were not collected from Key Informant Relatives or Key Informant Providers.
|
16 Participants
n=53 Participants • Cancer Stage data were not collected from Key Informant Relatives or Key Informant Providers.
|
|
Cancer Stage
Stage III
|
3 Participants
n=20 Participants • Cancer Stage data were not collected from Key Informant Relatives or Key Informant Providers.
|
—
|
—
|
8 Participants
n=33 Participants • Cancer Stage data were not collected from Key Informant Relatives or Key Informant Providers.
|
11 Participants
n=53 Participants • Cancer Stage data were not collected from Key Informant Relatives or Key Informant Providers.
|
|
Cancer Stage
Stage IV
|
1 Participants
n=20 Participants • Cancer Stage data were not collected from Key Informant Relatives or Key Informant Providers.
|
—
|
—
|
1 Participants
n=33 Participants • Cancer Stage data were not collected from Key Informant Relatives or Key Informant Providers.
|
2 Participants
n=53 Participants • Cancer Stage data were not collected from Key Informant Relatives or Key Informant Providers.
|
|
Marital Status
Single
|
8 Participants
n=20 Participants • Marital Status were not collected from Key Informant Providers.
|
5 Participants
n=15 Participants • Marital Status were not collected from Key Informant Providers.
|
—
|
10 Participants
n=33 Participants • Marital Status were not collected from Key Informant Providers.
|
23 Participants
n=68 Participants • Marital Status were not collected from Key Informant Providers.
|
|
Marital Status
Married/civil union/living together
|
10 Participants
n=20 Participants • Marital Status were not collected from Key Informant Providers.
|
10 Participants
n=15 Participants • Marital Status were not collected from Key Informant Providers.
|
—
|
16 Participants
n=33 Participants • Marital Status were not collected from Key Informant Providers.
|
36 Participants
n=68 Participants • Marital Status were not collected from Key Informant Providers.
|
|
Marital Status
Separated/divorced/widowed
|
2 Participants
n=20 Participants • Marital Status were not collected from Key Informant Providers.
|
0 Participants
n=15 Participants • Marital Status were not collected from Key Informant Providers.
|
—
|
7 Participants
n=33 Participants • Marital Status were not collected from Key Informant Providers.
|
9 Participants
n=68 Participants • Marital Status were not collected from Key Informant Providers.
|
|
Employment Status
Employed
|
10 Participants
n=20 Participants • Employment Status data were not collected from Key Informant Providers.
|
8 Participants
n=15 Participants • Employment Status data were not collected from Key Informant Providers.
|
—
|
13 Participants
n=33 Participants • Employment Status data were not collected from Key Informant Providers.
|
31 Participants
n=68 Participants • Employment Status data were not collected from Key Informant Providers.
|
|
Employment Status
Unemployed
|
3 Participants
n=20 Participants • Employment Status data were not collected from Key Informant Providers.
|
1 Participants
n=15 Participants • Employment Status data were not collected from Key Informant Providers.
|
—
|
12 Participants
n=33 Participants • Employment Status data were not collected from Key Informant Providers.
|
16 Participants
n=68 Participants • Employment Status data were not collected from Key Informant Providers.
|
|
Employment Status
Other (e.g., student)
|
6 Participants
n=20 Participants • Employment Status data were not collected from Key Informant Providers.
|
6 Participants
n=15 Participants • Employment Status data were not collected from Key Informant Providers.
|
—
|
8 Participants
n=33 Participants • Employment Status data were not collected from Key Informant Providers.
|
20 Participants
n=68 Participants • Employment Status data were not collected from Key Informant Providers.
|
|
Employment Status
Missing
|
1 Participants
n=20 Participants • Employment Status data were not collected from Key Informant Providers.
|
0 Participants
n=15 Participants • Employment Status data were not collected from Key Informant Providers.
|
—
|
0 Participants
n=33 Participants • Employment Status data were not collected from Key Informant Providers.
|
1 Participants
n=68 Participants • Employment Status data were not collected from Key Informant Providers.
|
|
Specialty of Providers
Physician
|
—
|
—
|
4 Participants
n=13 Participants • Specialty of Providers data were not collected from Key Informant Patients, Key Informant Relatives, or PINPOINT Digital Education Tool (Pilot Test).
|
—
|
4 Participants
n=13 Participants • Specialty of Providers data were not collected from Key Informant Patients, Key Informant Relatives, or PINPOINT Digital Education Tool (Pilot Test).
|
|
Specialty of Providers
Nurse
|
—
|
—
|
7 Participants
n=13 Participants • Specialty of Providers data were not collected from Key Informant Patients, Key Informant Relatives, or PINPOINT Digital Education Tool (Pilot Test).
|
—
|
7 Participants
n=13 Participants • Specialty of Providers data were not collected from Key Informant Patients, Key Informant Relatives, or PINPOINT Digital Education Tool (Pilot Test).
|
|
Specialty of Providers
Social Workers
|
—
|
—
|
2 Participants
n=13 Participants • Specialty of Providers data were not collected from Key Informant Patients, Key Informant Relatives, or PINPOINT Digital Education Tool (Pilot Test).
|
—
|
2 Participants
n=13 Participants • Specialty of Providers data were not collected from Key Informant Patients, Key Informant Relatives, or PINPOINT Digital Education Tool (Pilot Test).
|
|
Health Care System Distrust
|
—
|
—
|
—
|
26.6 Score (rang 9-45)
STANDARD_DEVIATION 5.1 • n=33 Participants • Household Income data were not collected from Key Informant Patients, Key Informant Relatives, or Key Informant Providers.
|
26.6 Score (rang 9-45)
STANDARD_DEVIATION 5.1 • n=33 Participants • Household Income data were not collected from Key Informant Patients, Key Informant Relatives, or Key Informant Providers.
|
|
Health Literacy
Extremely/quite a bit
|
—
|
—
|
—
|
23 Participants
n=33 Participants • Healthy Literacy data were not collected from Key Informant Patients, Key Informant Relatives, or Key Informant Providers.
|
23 Participants
n=33 Participants • Healthy Literacy data were not collected from Key Informant Patients, Key Informant Relatives, or Key Informant Providers.
|
|
Health Literacy
Somewhat
|
—
|
—
|
—
|
5 Participants
n=33 Participants • Healthy Literacy data were not collected from Key Informant Patients, Key Informant Relatives, or Key Informant Providers.
|
5 Participants
n=33 Participants • Healthy Literacy data were not collected from Key Informant Patients, Key Informant Relatives, or Key Informant Providers.
|
|
Health Literacy
A little bit/not at all
|
—
|
—
|
—
|
5 Participants
n=33 Participants • Healthy Literacy data were not collected from Key Informant Patients, Key Informant Relatives, or Key Informant Providers.
|
5 Participants
n=33 Participants • Healthy Literacy data were not collected from Key Informant Patients, Key Informant Relatives, or Key Informant Providers.
|
PRIMARY outcome
Timeframe: Immediately following completion of the PINPOINT intervention during the pilot testing session (same day; intervention and exit survey completed within approximately 30-40 minutes total).Population: All participants who completed both baseline and post-intervention surveys and remained eligible.
Measured using the 4-item Acceptability of Intervention Measure (AIM). Scores range from 1 to 5, with higher scores indicating greater acceptability. Cronbach's α = .85.
Outcome measures
| Measure |
PINPOINT Digital Education Tool (Pilot Test)
n=30 Participants
Newly diagnosed Black or African American adults with solid tumor cancers who used the PINPOINT digital education tool, a culturally tailored website providing information on precision oncology, clinical trials, and immunotherapy. The tool included interactive features such as videos, a chatbot, and downloadable communication aids. Participants completed pre- and post-intervention surveys
|
|---|---|
|
Acceptability of Intervention
|
4.11 Score (1-5 scale)
Standard Deviation 0.54
|
PRIMARY outcome
Timeframe: Immediately following completion of the PINPOINT intervention during the pilot testing session (same day; intervention and exit survey completed within approximately 30-40 minutes total).Population: All participants who completed both baseline and post-intervention surveys and remained eligible.
Measured using the 4-item Intervention Appropriateness Measure (IAM). Scores range from 1 to 5, with higher scores indicating greater appropriateness. Cronbach's α = .91.
Outcome measures
| Measure |
PINPOINT Digital Education Tool (Pilot Test)
n=30 Participants
Newly diagnosed Black or African American adults with solid tumor cancers who used the PINPOINT digital education tool, a culturally tailored website providing information on precision oncology, clinical trials, and immunotherapy. The tool included interactive features such as videos, a chatbot, and downloadable communication aids. Participants completed pre- and post-intervention surveys
|
|---|---|
|
Appropriateness of Intervention
|
4.04 Score (1-5 scale)
Standard Deviation 0.60
|
SECONDARY outcome
Timeframe: Baseline assessed before exposure to the PINPOINT intervention; follow-up assessed by survey within approximately 1 week after the participant's oncology consultation.Population: All participants who completed both baseline and post-intervention surveys and remained eligible.
Assessed using two researcher-developed items based on the intervention content. Scores ranged from 0 to 2, with higher scores indicating greater knowledge.
Outcome measures
| Measure |
PINPOINT Digital Education Tool (Pilot Test)
n=30 Participants
Newly diagnosed Black or African American adults with solid tumor cancers who used the PINPOINT digital education tool, a culturally tailored website providing information on precision oncology, clinical trials, and immunotherapy. The tool included interactive features such as videos, a chatbot, and downloadable communication aids. Participants completed pre- and post-intervention surveys
|
|---|---|
|
Knowledge About Precision Oncology
Baseline (Pre-intervention)
|
0.83 Score (0-2) scale
Standard Deviation 0.75
|
|
Knowledge About Precision Oncology
Post-intervention (after treatment decision)
|
1.20 Score (0-2) scale
Standard Deviation 0.81
|
SECONDARY outcome
Timeframe: Baseline assessed before exposure to the PINPOINT intervention; follow-up assessed by survey within approximately 1 week after the participant's oncology consultation.Population: All participants who completed both baseline and post-intervention surveys and remained eligible.
Assessed using 4 researcher-developed items based on the intervention content. Scores ranged from 0 to 4, with higher scores indicating greater knowledge.
Outcome measures
| Measure |
PINPOINT Digital Education Tool (Pilot Test)
n=30 Participants
Newly diagnosed Black or African American adults with solid tumor cancers who used the PINPOINT digital education tool, a culturally tailored website providing information on precision oncology, clinical trials, and immunotherapy. The tool included interactive features such as videos, a chatbot, and downloadable communication aids. Participants completed pre- and post-intervention surveys
|
|---|---|
|
Knowledge About Clinical Trials
Baseline (Pre-intervention)
|
2.07 Score (0-4) scale
Standard Deviation 1.05
|
|
Knowledge About Clinical Trials
Post-intervention (after treatment decision)
|
2.73 Score (0-4) scale
Standard Deviation 1.08
|
SECONDARY outcome
Timeframe: Baseline assessed before exposure to the PINPOINT intervention; follow-up assessed by survey within approximately 1 week after the participant's oncology consultation.Population: All participants who completed both baseline and post-intervention surveys and remained eligible.
Assessed using the 11-item Decision Self-Efficacy Scale. Scores ranged from 0 to 100, with higher scores indicating greater confidence in participants' ability to make informed decisions about tumor genomic sequencing.
Outcome measures
| Measure |
PINPOINT Digital Education Tool (Pilot Test)
n=30 Participants
Newly diagnosed Black or African American adults with solid tumor cancers who used the PINPOINT digital education tool, a culturally tailored website providing information on precision oncology, clinical trials, and immunotherapy. The tool included interactive features such as videos, a chatbot, and downloadable communication aids. Participants completed pre- and post-intervention surveys
|
|---|---|
|
Decision Self-efficacy for Tumor Genomic Sequencing.
Baseline (Pre-intervention)
|
78.11 Score (0-100 scale)
Standard Deviation 16.15
|
|
Decision Self-efficacy for Tumor Genomic Sequencing.
Post-intervention (after treatment decision)
|
79.92 Score (0-100 scale)
Standard Deviation 16.82
|
SECONDARY outcome
Timeframe: Baseline assessed before exposure to the PINPOINT intervention; follow-up assessed by survey within approximately 1 week after the participant's oncology consultation.Population: All participants who completed both baseline and post-intervention surveys and remained eligible.
Assessed using the 11-item Decision Self Efficacy Scale. Scored ranged from 0 to 100, with higher scored indicating greater confidence in participants' ability to make informed decisions about receiving targeted or immune therapies.
Outcome measures
| Measure |
PINPOINT Digital Education Tool (Pilot Test)
n=30 Participants
Newly diagnosed Black or African American adults with solid tumor cancers who used the PINPOINT digital education tool, a culturally tailored website providing information on precision oncology, clinical trials, and immunotherapy. The tool included interactive features such as videos, a chatbot, and downloadable communication aids. Participants completed pre- and post-intervention surveys
|
|---|---|
|
Decision Self-efficacy for Targeted/Immune Therapy
Baseline (Pre-Intervention)
|
77.12 Score (0-100) scale
Standard Deviation 23.60
|
|
Decision Self-efficacy for Targeted/Immune Therapy
Post-intervention (after treatment decision)
|
87.35 Score (0-100) scale
Standard Deviation 16.63
|
SECONDARY outcome
Timeframe: Baseline assessed before exposure to the PINPOINT intervention; follow-up assessed by survey within approximately 1 week after the participant's oncology consultation.Population: All participants who completed both baseline and post-intervention surveys and remained eligible.
Assessed using the 13-item Patient Activation Measure (PAM). Scores ranged from 0 to 100, with higher scores indicating greater levels of patient activation and empowerment in managing one's health and health care.
Outcome measures
| Measure |
PINPOINT Digital Education Tool (Pilot Test)
n=30 Participants
Newly diagnosed Black or African American adults with solid tumor cancers who used the PINPOINT digital education tool, a culturally tailored website providing information on precision oncology, clinical trials, and immunotherapy. The tool included interactive features such as videos, a chatbot, and downloadable communication aids. Participants completed pre- and post-intervention surveys
|
|---|---|
|
Patient Empowerment
Baseline (Pre-intervention)
|
64.67 Score (0-100) scale
Standard Deviation 14.34
|
|
Patient Empowerment
Post-intervention (after treatment decision)
|
68.4 Score (0-100) scale
Standard Deviation 19.28
|
Adverse Events
Key Informant Patients
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Key Informant Relatives
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Key Informant Providers
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
PINPOINT Digital Education Tool (Pilot Test)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place